Transformative Trends in Urology: Investor Event Announced
Exciting Investor Event Ahead for PROCEPT BioRobotics
PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a leader in surgical robotics aimed at transforming patient care, is gearing up for an important investor event in an upcoming urological conference. Set to take place at the renowned Venetian Hotel in Las Vegas, this event offers a unique insight into the future of urology on a significant platform for healthcare professionals.
Event Details and Management Team
The investor event is scheduled for a Friday morning, with an itinerary designed to maximize engagement and information sharing. Attendees will hear from key members of PROCEPT BioRobotics' management team. This includes:
- Reza Zadno – Chief Executive Officer
- Kevin Waters – Chief Financial Officer
- Sham Shiblaq – Chief Commercial Officer
- Barry Templin – Chief Technology Officer
The presence of these executives signifies the company's commitment to transparency and investor engagement, showcasing their robust leadership as they navigate the evolving landscape of medical technology.
Clinical Insights for Enhanced Understanding
To enrich the discourse, clinical perspectives will be shared by notable physicians who specialize in urology. These influential figures will provide valuable insights, shedding light on the innovative treatments that PROCEPT BioRobotics is pioneering in the field. The clinical expertise from:
- Dr. Inderbir Gill - Renowned leader in urology from USC
- Dr. Brian Helfand - Esteemed academic and clinical professor at the University of Chicago
- Dr. Gerald Park - Partner at Kansas City Urology Care
Each clinical speaker brings a wealth of knowledge and experience, creating an environment ripe for learning about groundbreaking surgical solutions.
Webcast Accessibility and Financial Reporting
For those unable to attend in person, PROCEPT BioRobotics will live stream the event, ensuring broader access for interested investors. The webcast will be archived on the company's official website, allowing for replays and continued engagement for at least 90 days post-event.
In addition, the company plans to report on its financial performance shortly before this investor event, providing a comprehensive overview of its market standing as they discuss future trajectories. A dedicated conference call will follow to delve deeper into the financial results, enabling investors to directly engage with management and ask pertinent questions.
Innovations in Urology: The Role of PROCEPT BioRobotics
PROCEPT BioRobotics is not just attending these high-profile events; they are at the forefront of revolutionizing surgical procedures in urology. Known for their AQUABEAM and HYDROS Robotic Systems, the company harnesses cutting-edge technology to enhance patient outcomes through procedures like Aquablation therapy. This advanced therapy is designed to treat lower urinary tract symptoms related to BPH effectively, regardless of prostate size or complexity.
With an impressive library of clinical evidence, including over 150 peer-reviewed publications, the benefits and advantages of Aquablation therapy are increasingly recognized within the medical community. The company’s rigorous research underscores its commitment to improving healthcare delivery methods.
Safety and Side Effect Awareness
While advancements in surgical robotics offer many benefits, it is crucial to be aware of the potential side effects associated with all forms of surgery. PROCEPT BioRobotics emphasizes patient care and safety, providing detailed information regarding potential risks associated with their procedures. This aligns with their mission to not only offer innovative solutions but also ensure patients are fully informed about their treatment options.
How to Engage with PROCEPT BioRobotics
For those interested in further information or specific inquiries, PROCEPT BioRobotics has made it easy for investors and healthcare professionals to connect. Matt Bacso, VP of Investor Relations and Business Operations, is available for any questions. His direct contact fosters an open line of communication that is vital for investor relations.
Frequently Asked Questions
What is the purpose of the upcoming investor event?
The investor event aims to provide insights into PROCEPT BioRobotics’ advancements in surgical robotics, alongside financial updates and clinical perspectives.
When will the event take place?
The event will be held at the Venetian Hotel in Las Vegas at the AUA Annual Meeting.
Who will be speaking at the event?
Key executives and leading physicians in urology will present at the event, sharing their expertise and insights.
Is there a way to access the event if I can’t attend in person?
Yes, the event will be streamed live, and an archived recording will be available for those who wish to watch it later.
What are the key products offered by PROCEPT BioRobotics?
PROCEPT BioRobotics offers advanced robotic systems such as the AQUABEAM and HYDROS, focusing on innovative treatments for men suffering from BPH.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
